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TGFβ is a potent regulator of several biological functions in many cell types, but its role in the diﬀerentiation of human bone
marrow-derived skeletal stem cells (hMSCs) is currently poorly understood. In the present study, we demonstrate that a single
dose of TGFβ1 prior to induction of osteogenic or adipogenic diﬀerentiation results in increased mineralized matrix or
increased numbers of lipid-ﬁlled mature adipocytes, respectively. To identify the mechanisms underlying this TGFβ-
mediated enhancement of lineage commitment, we compared the gene expression proﬁles of TGFβ1-treated hMSC cultures
using DNA microarrays. In total, 1932 genes were upregulated, and 1298 genes were downregulated. Bioinformatics
analysis revealed that TGFβl treatment was associated with an enrichment of genes in the skeletal and extracellular matrix
categories and the regulation of the actin cytoskeleton. To investigate further, we examined the actin cytoskeleton following
treatment with TGFβ1 and/or cytochalasin D. Interestingly, cytochalasin D treatment of hMSCs enhanced adipogenic
diﬀerentiation but inhibited osteogenic diﬀerentiation. Global gene expression proﬁling revealed a signiﬁcant enrichment of
pathways related to osteogenesis and adipogenesis and of genes regulated by both TGFβ1 and cytochalasin D. Our study
demonstrates that TGFβ1 enhances hMSC commitment to either the osteogenic or adipogenic lineages by reorganizing the
actin cytoskeleton.
1. Introduction
Fat and bone tissues both originate from bone marrow
progenitor cells called skeletal stem cells, also known as
bone marrow-derived multipotent stromal cells or
mesenchymal stem cells (MSCs). The formation of these
tissues is regulated throughout an organism’s lifetime by
homeostatic mechanisms within the marrow cavity. It
has been suggested that an imbalance between osteogenic
and adipogenic lineage commitment and diﬀerentiation is
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responsible for age-related impairment of bone formation,
and a number of therapeutic interventions targeting and acti-
vating MSCs, thus enhancing bone mass, have been pro-
posed. Indeed, the identiﬁcation of novel strategies to steer
human skeletal (mesenchymal) stem cell diﬀerentiation
towards the production of osteoblastic cells, thus increasing
bone formation, is very topical in the bone biology ﬁeld.
The transforming growth factor (TGF) superfamily con-
sists of over 40 members, including activins, inhibins, bone
morphogenetic proteins (BMPs), growth and diﬀerentiation
factors (GDFs), and TGFβs [1]. TGF family members are
multifunctional regulators of cell growth and diﬀerentiation,
playing pivotal roles during embryonic development, organ-
ogenesis, and tissue homeostasis [2]. The cytokine TGFβ1 is
among the most abundant in bone matrix [3] and is secreted
by endothelial cells, epithelial cells, ﬁbroblasts, smooth mus-
cle cells, and most immune cells [4]. TGFβ1 is deposited in
bone matrix as an inactive, latent complex with latency-
associated protein (LAP), the binding of which masks the
receptor domains of active TGFβ1. During bone formation,
osteoclast-mediated bone resorption activates TGFβ1 by
cleaving LAP and releasing it from bone matrix, thus creat-
ing a transient gradient of active TGFβ1 that attracts MSCs
to bone remodeling sites, where they undergo osteoblastic
diﬀerentiation [5]. Furthermore, TGFβ1 is known to regu-
late the proliferation and diﬀerentiation of osteoprogenitor
cells [6].
Actin microﬁlaments are composed of polymers of actin,
the most abundant cellular protein which also forms the
thinnest part of the cytoskeleton, and are primarily responsi-
ble for skeletal structure [7]. Cellular actin exists in two
forms, ﬁlamentous polymerized actin (F-actin) and globu-
lar/monomer depolymerized actin (G-actin), and transitions
between these forms during highly dynamic intracellular
polymerization and depolymerization processes [8]. In mam-
mals, actin polymerization factors regulate actin polymeriza-
tion and depolymerization [9]. While the stiﬀness of actin is
lower than that of microtubules, actin molecules form a
highly organized structural network, supported by a large
number of interacting cross-linking proteins, which together
confer a substantial amount of mechanical strength [10]. The
cytoskeleton is known to be important for determining cell
morphology and for mediating changes in adhesion and dif-
ferentiation [11]. Indeed, during human MSC (hMSC) line-
age commitment, cells undergo signiﬁcant morphological
changes and actin cytoskeletal reorganization which contrib-
ute to the determination of cellular fate [7, 12].
In this study, we investigated the eﬀect of TGFβ-induced
actin cytoskeleton modiﬁcations on the potential of hMSCs
to diﬀerentiate into osteogenic and adipogenic lineages, as
well as the eﬀect of the actin polymerization inhibitor cyto-
chalasin D (CYD). Our data suggest that TGFβ-induced
actin cytoskeleton reorganization is a prerequisite for hMSC
diﬀerentiation into osteocytic or adipocytic lineages.
2. Results
2.1. TGFβ1 Treatment Enhanced the Osteogenic Diﬀerentiation
of hMSCs. A single treatment with TGFβ1 (10ng/ml, for 2
days) enhanced hMSC osteogenic diﬀerentiation, as shown
by the increased mineralized matrix formation made evident
by alizarin red S staining (Figures 1(a) and 1(b)). Conversely,
when TGFβ1 signaling was blocked with the inhibitor SB-
431542 (10μM), signiﬁcantly lower mineralized matrix for-
mation was observed (Figures 1(a) and 1(b)). Consistent with
this, higher expression of the osteoblastic genes alkaline phos-
phatase (ALP), runt-related transcription factor 2 (RUNX2),
and osteocalcin (OCN) was observed in hMSCs undergoing
osteogenic diﬀerentiation in the presence of TGFβ1, while
treatment with the TGFβ1 inhibitor SB-431542 severely
inhibited this expression (Figure 1(c)).
2.2. TGFβ1 Treatment Enhanced the Adipogenic Diﬀerentiation
of hMSCs.Next, we examined the eﬀect of treating hMSCs with
a single dose of TGFβ1 (10 ng/ml, for 2 days) on adipo-
genic diﬀerentiation. We found that adipogenic diﬀerenti-
ation was enhanced following TGFβ1 treatment, as shown
by an increase in the number of lipid-ﬁlled adipocytes
(Figures 1(d) and 1(e)). Similarly, the expression of several
adipogenic gene markers, including lipoprotein lipase
(LPL), peroxisome proliferator-activated receptor gamma
2 (PPARG-2), adipocyte protein 2 (aP2), and ADIPOQ,
was upregulated following TGFβ1 treatment, while treat-
ment with SB-431542 reversed these eﬀects (Figure 1(f)).
2.3. TGFβ1 Stimulation Has No Eﬀect on hMSC Viability or
Proliferation. The eﬀect of TGFβ1 on hMSC cell viability
was assessed using alamarBlue assay reagent. No signiﬁcant
eﬀect on viability was observed after 4 days of treatment
(Figure 2(a)). To investigate the eﬀect of TGFβ1 on cellular
proliferation, we used the xCELLigence RTCA DP® cell pro-
liferation assay system, which allows the continuous moni-
toring of cell numbers over time. As shown in Figure 2(b),
there was no measurable diﬀerence in hMSC proliferation
in the presence or absence of TGFβ1.
2.4. Molecular Phenotype of TGFβ1-Treated hMSCs. To
understand the molecular mechanisms underlying the
TGFβl-mediated regulation of hMSC diﬀerentiation, we
compared global gene expression in TGFβl-treated hMSCs
and vehicle-treated control cells using microarray analysis.
In total, 1932 gene transcripts were signiﬁcantly upregulated,
and 1298 were signiﬁcantly downregulated following TGFβl
treatment. Signiﬁcant changes were deﬁned as a fold
change≥ 2, p < 0 05 and are listed in Supplementary Tables
S1 and S2. Hierarchical clustering of diﬀerentially expressed
genes revealed a clear distinction between TGFβl-treated
and control samples (Figure 3(a)). Next, we used performed
gene ontology analysis to identify the biological processes
that were favored following TGFβl treatment. We found that
the genes that were signiﬁcantly altered in TGFβl-treated
MSCs were enriched within several skeletal and extracellular
matrix categories, including extracellular matrix (53 genes),
extracellular matrix organization (51 genes), and proteina-
ceous extracellular matrix (Supplementary Table S3). Fur-
thermore, pathway analysis of signiﬁcantly changed genes
revealed the signiﬁcant enrichment of several signaling path-
ways in TGFβl-treated hMSCs. Among these, the most
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Figure 1: TGFβ1 induces osteogenic and adipogenic diﬀerentiation. MSCs underwent osteogenic or adipogenic diﬀerentiation by culturing
cells in the appropriate medium for 7 days. (a) Micrographs showing the degree of mineralized calcium deposition in noninduced cells (NI),
osteoinduced cells (OS), osteoinduced cells + SB-431542 (OS + SB), and osteoinduced cells + TGFβ1 (OS +TGFB), as assessed by alizarin
red S staining (20x magniﬁcation). (b) Quantiﬁcation of mineralization in the alizarin red S stained groups shown in (a). Data are
shown as the mean± SD of three independent experiments (∗∗∗p < 0 005). (c) mRNA expression of the osteogenic markers ALPL,
RUNX2, and OCN, normalized to GAPDH, as determined by RT-PCR. Data are shown as the mean± SD of three independent
experiments (∗p < 0 05; ∗∗∗p < 0 0005). (d) Micrographs showing the accumulation of lipid droplets in noninduced cells (NI),
adipoinduced cells (AD), adipoinduced cells + SB-431542 (AD+ SB), and adipoinduced cells + TGFβ1 (AD+TGFB), as determined by Oil
red O staining (20x magniﬁcation). (e) Quantiﬁcation of mature adipocytes in the NI, AD, AD+ SB, and AD+TGFB groups, as
determined by Nile red ﬂuorescence intensity. Data are shown as the mean± SD of three independent experiments (∗∗∗p < 0 005). (f)
mRNA expression of the adipogenic markers LPL, aP2, PPARG-2, and ADIPOQ, normalized to GAPDH, as determined by RT-PCR. Data
are shown as the mean± SD of three independent experiments (∗p < 0 05; ∗∗∗p < 0 0005).
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enriched pathways were “regulation of actin cytoskeleton,”
“MAPK signaling,” “focal adhesion,” “TGFβ1 signaling,”
“adipogenesis,” “endochondral ossiﬁcation,” and “osteoblast
signaling” (Figure 3(b)). Table 1 lists the genes within osteo-
genesis- and adipogenesis-related signaling pathways that
were upregulated in TGFβ1-treated cells. A selected panel
of genes known to be involved in cell diﬀerentiation and
TGFβ signaling that were signiﬁcantly changed in the micro-
array data were examined by qRT-PCR. In general, a good
degree of concordance was observed between the microarray
and qRT-PCR data (Figure 3(c)).
2.5. Actin Microﬁlaments in MSCs Are Altered following
Treatment with TGFβ1 or the Actin Polymerization Inhibitor
CYD. Our molecular phenotyping analysis of TGFβl-
treated hMSCs revealed a signiﬁcant enrichment of genes
associated with cytoskeletal changes. Based on this, and
on our previous observations that TGFβl treatment triggers
signiﬁcant morphological changes in hMSCs, we examined
the eﬀect of TGFβl on the cytoskeleton using transmis-
sion electron microscopy (TEM), which has the power to
reveal structural changes in actin microﬁlaments. Actin
microﬁlament polymerization was found to be inhibited in
cells treated with either the potent actin polymerization
inhibitor CYD or the TGFβ inhibitor SB-431542. In contrast,
TGFβ1 treatment was associated with a prominent distribu-
tion of actin ﬁlaments, organized as bundles/aggregates, in
the perinuclear area and at one cell pole (Figure 4). The ultra-
structural characteristics of the cells under the various treat-
ment conditions are summarized in Supplementary Table S4.
2.6. CYD Regulates Osteogenic and Adipogenic Diﬀerentiation
in the Presence of TGFβ1. To conﬁrm that TGFβ1 regulates
actin cytoskeletal dynamics, hMSCs undergoing either osteo-
genic or adipogenic diﬀerentiation were treated with TGFβ1
in the absence or presence of the actin polymerization inhib-
itor CYD. CYD treatment signiﬁcantly inhibited hMSC oste-
ogenic diﬀerentiation in both the presence and absence of
TGFβl, as shown by reduced mineralization (Figure 5(a)).
Similarly, expression of the osteogenic marker genes ALPL,
RUNX2, and OCN was inhibited by CYD treatment, with
and without TGFβl (Figure 5(b)). Conversely, CYD treat-
ment enhanced hMSC adipogenic diﬀerentiation, as shown
by a greatly increased number of lipid-ﬁlled mature adipo-
cytes and the increased expression of the adipogenic
marker genes LPL and PPARG-2. These eﬀects were main-
tained when cells were treated concomitantly with TGFβl
(Figures 5(c) and 5(d)).
2.7. Molecular Phenotype of CYD-Treated Cells. The data pre-
sented above suggest that CYD and TGFβ1 target similar
molecular pathways during hMSC osteogenic and adipogenic
diﬀerentiation. In order to investigate this further and to
elucidate the molecular mechanisms underlying the CYD-
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Figure 2: TGFβ1 does not aﬀect hMSC proliferation or viability. (a) Chart showing the relative hMSC viability in the absence (CNT) or
presence (TGFB1) of TGFβ1, as determined by alamarBlue assay reagent. Shown are cell viabilities on days 2 (D2), 3 (D3), and 4 (D4) of
culture. (b) Real-time proliferation assay data using the xCELLigence RTCA DP system for hMSC cells with and without TGFβ1
treatment. Lower panel: cell proliferation was measured at 15-minute intervals for a total duration of 24 hours. Upper panel: summary
data showing cellular proliferation after 24 hours. Data are shown as the mean± SD of two independent experiments (n = 6). NS: not
signiﬁcant.
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mediated eﬀects on hMSC diﬀerentiation, microarray analy-
sis was performed to establish global gene expression proﬁles
for CYD-treated and controls cells. In total, 10,855 genes
were signiﬁcantly upregulated, and 2523 genes were signiﬁ-
cantly downregulated following CYD treatment. Genes were
deﬁned as signiﬁcantly changed if they had a fold change≥ 2
and p < 0 05 and are listed in Supplementary Tables S5 and
S6. As was seen with TGFβ1 treatment, hierarchical cluster-
ing of the diﬀerentially expressed genes revealed a clear
distinction between untreated and CYD-treated hMSCs
(Figure 6(a)). Pathway analysis of these genes revealed sev-
eral molecular pathways that were enriched upon CYD treat-
ment (Figure 6(b)). Among the most signiﬁcant were
pathways involved in the regulation of the actin cytoskeleton,
focal adhesion signaling, endochondral ossiﬁcation, TGFβ1
signaling, regulation of the microtubule cytoskeleton, and
MAPK signaling (Figure 6(b)). The genes that are associated
with these pathways that were upregulated in CYD-treated
cells are listed in Table 2. Forty-two genes that are involved
in adipogenesis-related pathways were signiﬁcantly enriched
in CYD-treated cells (Table 3). Interestingly, 218 genes were
both upregulated in TGFβ1-treated hMSCs and downregu-
lated in CYD-treated hMSCs (Figure 6(c)), showing that
the molecular signature on CYD treatment is the inverse of
that seen with TGFβ1 treatment and suggesting that these
genes may be involved in TGFβ-mediated cytoskeletal reor-
ganization (Table 4).
3. Discussion
TGFβ is a potent regulator of various biological functions in
many cell types, but its eﬀects on hMSC diﬀerentiation are, to
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Figure 3: Molecular phenotype of TGFβ1-treated hMSCs. (a) Hierarchical clustering of genes that were diﬀerentially expressed in TGFβl-
treated and untreated control (CNT) hMSCs. Rows represent individual gene expression for duplicate treated and untreated samples, as
indicated. Columns represent individual transcripts. Relative expression levels are presented colorimetrically, according to the scale shown
in the color bar. (b) Pie chart showing the pathways with the highest enrichment of genes signiﬁcantly upregulated in TGFβ1-treated cells.
(c) qRT-PCR validation of selected genes that were upregulated in the microarray data (n = 3, ∗p < 005; ∗∗∗p < 0001). Cells treated with
vehicle (DMSO) were used as controls.
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date, poorly understood. In the present study, we contribute
to this understanding and demonstrate that TGFβ can
enhance both osteoblastic and adipocytic lineage commit-
ment by modulating changes to the actin cytoskeleton.
TGFβ1 is known to regulate the proliferation anddiﬀeren-
tiation of osteoprogenitor cells [6, 13–15], and it reportedly
stimulates bone matrix apposition and bone cell replication
[16]. Several studies have demonstrated that TGFβ1 promotes
bone formation in vitro by recruiting osteoblast progenitors
and inducingbonematrix formationat early stages of diﬀeren-
tiation. In addition to this direct regulation of bone formation,
TGFβ1, along with BMPs, enhances RUNX2 expression at
early diﬀerentiation stages [17]. This is consistent with our
ﬁnding thatTGFβ1promotedosteogenesis andwas associated
with the upregulation of the osteogenic genes ALPL, RUNX2,
andOCN.
Furthermore, we showed that TGF-β1 treatment
enhanced the in vitro adipocytic diﬀerentiation of hMSCs.
This is consistent with several previously reported studies
which demonstrate that TGFβ1 has a positive eﬀect on
adipogenic diﬀerentiation under speciﬁc culture conditions
[18, 19]; an early study considering rat brown adipocytes
showed an upregulation of lipogenic enzymes following
TGFβ1 treatment [19].
Our results showed that TGFβ1 treatment did not aﬀect
MSC cell growth in vitro. Previously, conﬂicting results have
been published; some studies reported that TGFβ1 regulated
osteoprogenitor proliferation in vitro [13, 20], whereas Yu et
al. reported that TGFβ1 treatment strongly inhibited the
proliferation of human lung epithelial cells [21]. The
mitogenic eﬀects of TGFβ on cells are reportedly variable;
while progressive mitogenesis was stimulated in conﬂuent
cells following treatment with 0.15–15ng/ml TGFβ, in sparse
cultures 0.15 ng/ml TGFβ exhibited inhibitory eﬀects. How-
ever, at all cell densities, 15 ng/ml TGFβ stimulated collagen
synthesis, with this eﬀect being most pronounced when DNA
synthesis was declining [22]. Most of the published data on
TGFβ has shown a mitogenic eﬀect on osteoprogenitors
[16, 23–26], but relatively few studies have examined the
growth inhibitory eﬀect of this cytokine on osteoblast-like
cells [27, 28]. It is likely that these contradictory observations
reﬂect the fact that the eﬀect TGFβ has on cellular prolif-
eration is dependent upon TGFβ concentration, culture
conditions including cell density, the cell model system
(tumorigenic versus nontumorigenic), the diﬀerentiation
stage of the target cell population, and/or the presence of
other growth factors.
The cytoskeleton is known to be important for cell
morphology and for mediating changes in adhesion and dif-
ferentiation [11]. Furthermore, signiﬁcant changes in cyto-
skeletal components reportedly occur during hMSC lineage
commitment and diﬀerentiation [7, 11]. While changes in
cell shape can be inﬂuenced by diﬀerentiation, several studies
have shown that the diﬀerentiation of precommitted mesen-
chymal stem cells is itself inﬂuenced by changes in cellular
morphology resulting from the altered expression of cadher-
ins, integrins, and cytoskeletal proteins [29]. Recently, the
inhibition of actin depolymerization was shown to enhance
both hMSC diﬀerentiation into osteoblasts and in vivo
bone formation, with these eﬀects being mediated by several
Table 1: Osteogenesis- and adipogenesis-related genes, from the most enriched pathways, that are upregulated in TGFβ1-treated cells.
Endochondral ossiﬁcation Actin cytoskeleton Focal adhesion TGFβ signaling MAPK signaling Adipogenesis
VEGFA FGF2 COL11A1 SMURF1 MAPK8 FOXO1A
ADAMTS4 FGFR1 COL3A1 MAPK8 NGFB TRIB3
PLAT4 TMSB4X COL4A1 SKP1 PDGFRB PCK2
COL10A1 GNA13 COL4A2 NEDD9 RASA2 EGR2
TGFB2 PDGFA COL4A4 ETS1 SOS2 DDIT3
PTHrP FGF1 COL5A1 KLF11 KRAS GADD45A
FGF2 ENAH COL5A2 ATF3 MRAS GADD45B
C4ST1 MSN COL1A1 FOSB NF1 HIF1A
FGFR1 GSN LAMC2 SKIL RAP1B IRS1
PDGFRB PDGFRB THBS2 SMURF1 DUSP1 MEF2D
COL1 KRAS CAV2 ZFYVE16 DDIT3 FAS
MRAS ARHGAP5 HSPB1 SPOCK
SOS2 PTEN IL1A
AKT3 FAS
PDGFA TGFB2
PDGFC MAP313
PGF ZAK
ITGA2 AKT3
PDGFRB MAP3K8
RAP1B GADD45A
MAPK8
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signaling pathways and involving focal adhesion kinase
(FAK), p38, and JNK activation [7]. Furthermore, a separate
study reported that the suppression of actin polymerization,
a very early event in hMSC diﬀerentiation, following the
downregulation of p38MAPK activity, inhibited osteogenesis
[30]. Additionally, α-smooth muscle actin is important for
both the identiﬁcation of osteoprogenitors in hMSCs and
their diﬀerentiation fate [31], and Rho GTPase-mediated
cytoskeletal modiﬁcation is essential for controlling hMSC
diﬀerentiation and migration [32].
On the other hand, adipocytic diﬀerentiation is associated
with the morphological change from ﬁbroblast-like cells to
spherical cells ﬁlled with fat droplets [33]. These morphologi-
cal alterationsare alsoassociatedwithcytoskeletal changes and
CNT +SB +TGFB1 +CYD
2 휇m 2 휇m 2 휇m 5 휇m
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Figure 4: Transmission electron microscopy of MSCs with and without treatment with SB-431542, TGFβ1, or CYD. TEM ultrastructural
analysis of MSCs following no treatment (CNT) or treatment with SB-431542 (SB), TGFβ1, or CYD. Increasing levels of magniﬁcation are
indicated by scale bars. N: nucleus; Nu: nucleolus; AC: actin ﬁlaments; V: microvilli; M: mitochondria; PL: primary lysosome; SL:
secondary lysosome; rER: rough endoplasmic reticulum; G: Golgi bodies; B: cell blebs; P: cell processes; IF: nuclear membrane infolding;
EV: endocytotic vacuole.
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Figure 5: Inhibition of actin polymerization promotes adipogenic diﬀerentiation but inhibits osteogenic diﬀerentiation in MSCs. MSCs
underwent osteogenic or adipogenic diﬀerentiation by culturing cells in the appropriate medium for 7 days. Cells also underwent the
indicated treatments. (a) Mineralized calcium deposition, as determined by alizarin red S staining in MSCs that were osteoinduced (OS),
osteoinduced with TGFβ1 treatment two days prior to induction (OS +TGFβ1), osteoinduced with CYD treatment at the onset of
induction (OS +CYD), or osteoinduced with both TGFβ1 and CYD treatment at the time points described above (OS +TGFβ1 +CYD).
Lower panel: micrograph of stained wells. Upper panel: quantiﬁcation of mineralized matrix formation under the indicated treatment
conditions. Data are shown as the mean± SD of three independent experiments (∗p < 0 05; ∗∗∗p < 0 005). (b) Gene expression of the
osteogenic markers ALPL, RUNX2, and OCN, normalized to GAPDH, as determined by qRT-PCR. Cells were either not induced (NI) or
induced under the conditions described in (a). Data are shown as the mean± SD of three independent experiments (∗p < 0 05; ∗∗p < 0 005,
∗∗∗p < 0 0005). (c) Adipogenic diﬀerentiation of MSCs that were adipoinduced (AD), adipoinduced with TGFβ1 treatment 2 days prior to
induction (AD+TGFβ1), adipoinduced with CYD treatment, initiated at the onset of induction (AD+CYD), or adipoinduced with both
TGFβ1 and CYD treatment at the time points described above (AD+TGFβ1 +CYD). Lower panel: Oil red O staining of the indicated
cells. Upper panel: Nile red quantiﬁcation of oil content under the indicated conditions. (d) Gene expression of the adipogenic marker
genes PPARG and LPL, determined by qRT-PCR and normalized to GAPDH, under the indicated treatment regimens. Data are shown as
the mean± SD of three independent experiments (∗∗p < 0 005, ∗∗∗p < 0 0005). All controls were treated with vehicle only.
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actin reorganization, which takes place in the early lineage
commitment stage, prior to the upregulation of many
adipocytic-speciﬁc gene markers [34]. The diﬀerentiation of
hMSCs into the adipocytic lineage in vitro is known tobe inﬂu-
enced by the cytoskeletal tension that results following actin
reorganization [32]. Furthermore, TGFβ1 Ca2+ signaling is
known to regulate osteoblast adhesion through enhanced
α5 integrin expression, the formation of focal contacts,
and the mediation of cytoskeleton reorganization [35, 36].
Additionally, the TGFβ1-mediated stimulation of DNA
synthesis in mouse osteoblastic cells is reportedly associated
with morphological changes and is accompanied by the
enhanced synthesis and polymerization of cytoskeletal pro-
teins [37]. Consistent with this, our data suggests that
TGFβ1 enhances hMSC lineage commitment by regulating
the morphology of the actin cytoskeleton, focal adhesion,
and endochondral ossiﬁcation, via the TGFβ1 and MAPK
signaling pathways.
Also consistent with our results are reports that CYD-
mediated reductions in actin polymerization stimulate
adipogenesis, but inhibit osteogenesis [30], suggesting that
cytoskeletal modiﬁcation is a prerequisite for cell fate deter-
mination. Our gene expression proﬁling revealed that the
genes FGF1, FGF2, and KRAS, which commonly regulate
actin cytoskeleton reorganization, were upregulated and
downregulated in TGFβ1- and CYD-treated cells, respec-
tively, suggesting that they are involved in the actin
polymerization-mediated diﬀerentiation of MSCs.
We showed that during osteogenesis, TGFβ1 treatment
reorganized the cytoskeleton, but this reorganization, and
thus osteogenesis, could be disturbed by CYD treatment.
Conversely, treatment with either TGFβ1 or CYD promoted
adipogenesis. This observation can potentially be explained
by considering that TGFβ1 and CYD promote the formation
of diﬀerent cytoskeleton patterns, both of which support adi-
pogenesis. Alternatively, it is possible that cytoskeletal reor-
ganization leading to adipogenesis can be promoted by
both TGFβ1-dependent and -independent mechanisms,
and that CYD-mediated cytoskeletal reorganization cannot
override the TGFβ1-independent mechanism.
We propose a model wherein TGFβ1 regulates cytoskel-
etal organization by modulating actin cytoskeleton-related
genes, leading to enhanced hMSC diﬀerentiation into both
osteoblasts and adipocytes (Figure 7). We propose that
CYD enhances adipogenesis and inhibits osteogenesis by reg-
ulating the expression of a number of key candidate genes,
including FGF2, TGFβ2, Plat, EGR2, MEF2D, and IRS1.
These genes were modulated by both TGFβ1 and CYD and
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Figure 6: Molecular phenotype of CYD-treated hMSCs. (a) Hierarchical clustering of genes that were diﬀerentially expressed in CYD-treated
and untreated control (CNT) hMSCs. Rows represent individual gene expression for duplicate treated and untreated samples, as indicated.
Columns represent individual transcripts. Relative expression levels are presented colorimetrically, according to the scale shown in the
color bar. (b) Pie chart showing the pathways with the highest enrichment of genes signiﬁcantly upregulated in CYD-treated cells. (c)
Venn diagram depicting the overlap between the upregulated genes in TGFβ1-treated cells (UP TGFβ1 versus CNT) and the
downregulated genes in CYD-treated cells (DOWN CYD versus CNT).
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are thus heavily implicated in the determination of hMSC
fate. In summary, our study provides novel molecular
insights into the role of the intracellular TGFβ signaling
pathway in bone and bone marrow adipose tissue formation.
This signaling involves the reorganization of the actin cyto-
skeleton in order to control the lineage-speciﬁc diﬀerentia-
tion of hMSCs.
4. Materials and Methods
4.1. Cell Culture. An hMSC-TERT cell line was created previ-
ously to serve as a model of human primary MSCs by overex-
pressing human telomerase reverse transcriptase (hTERT) in
normal human bone marrow MSCs [38]. This cell line has
been extensively characterized and exhibits a similar cellular
and molecular phenotype to primary MSCs [39]. For the cur-
rent experiments, we used a previously characterized subline
derived from hMSC-TERT cells, termed hMSC-TERT-CL1
[40]. For ease, this cell line is referred to as “hMSC” for the
remainder of the manuscript. Cells were cultured in Dulbec-
co’s modiﬁed Eagle’s medium (DMEM) supplemented with
4500mg/l D-glucose, 4mM L-glutamine, 110mg/l sodium
pyruvate, 10% fetal bovine serum (FBS), 1× penicillin/strep-
tomycin (pen/strep), and nonessential amino acids. All
reagents were purchased from Gibco, USA.
4.2. In Vitro Osteoblastic Diﬀerentiation. To induce osteo-
blastic diﬀerentiation, cells were initially grown in standard
DMEM growth medium in 6-well plates at a density of
0.3× 106 cells/ml. Once 70–80% conﬂuence was reached,
the medium was replaced with DMEM supplemented with
osteoblast induction mixture, containing 10% FBS, 1% pen/
strep, 50μg/ml L-ascorbic acid (Wako Chemicals, Neuss,
Germany), 10mM β-glycerophosphate (Sigma), 10 nM calci-
triol (1α,25-dihydroxyvitamin D3; Sigma), and 10nM dexa-
methasone (Sigma). The medium was replaced 3 times per
week. Cells were cultured in standard culture medium in par-
allel as controls.
Table 2: Genes involved in osteogenesis-related pathways that are
downregulated in CYD-treated hMSCs.
Endochondral
ossiﬁcation
Actin
cytoskeleton
Focal
adhesion
TGFβ
signaling
MAPK
signaling
FGF2 FGF1 ITGA6 UCHL5 STMN1
TGFB2 FGF2 STYK1 CDC2 DUSP1
PLAT FGF5 CAV1 SMURF2 TRAF2
CALM1 FGF22 CAV2 NEDD9 BDNF
ADAMTS1 KRAS CAV3 STAMBPL1 MAP3K5
OPG NRAS LAMC2 CCNB2 ACVR1C
C11orf13 THBS1 RBL1 KRAS
F2R PXN MAPK8 TGFB2
CRK RHOB PARD6A NRAS
PAK1 PDPK1 CAV1 PPP5C
ARHGEF7 MYLK2 TFDP1 PAK1
VIL2 PAK1 KLF6 CRK
PXN MAPK8 FST MAPK8
BCL2 SERPINE1
CCND3 THBS1
CRK NOG
HRAS
Table 3: Genes involved in adipogenesis-related pathways that are
upregulated in CYD-treated hMSCs.
Gene symbol Fold change versus control
PPARGC1A 2.4170778
AGT 15.447543
GDF10 9.77814
BMP2 9.539022
UCP1 9.416412
SFRP4 6.513523
IRS4 5.973821
MEF2C 5.1696005
LPL 5.150721
PLIN1 5.144724
LEP 5.1005282
NDN 5.0982733
CNTFR 4.9715867
LIF 3.9070668
PRLR 3.855135
RXRG 3.8392398
EGR2 3.6894956
PCK1 3.6815107
CYP26A1 3.170688
TGFBI 3.1407108
STAT2 3.0656292
BMP3 2.9982927
IGF1 2.9808753
PTGIS 2.8547947
INSR 2.8151898
SLC2A4 2.747039
CEBPB 2.7001002
IRS1 2.5992496
LPIN1 2.579549
AHRR 2.5087466
IL6 2.4654725
IRS2 2.3497624
STAT5A 2.2441745
CEBPA 2.2439373
SCD 2.216643
STAT1 2.205384
SPOCK1 2.201062
SREBF1 2.0996578
EPAS1 2.0842645
MEF2D 2.0606902
BMP1 2.0168457
LPIN3 2.0103807
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4.3. In Vitro Adipocytic Diﬀerentiation. To induce adipocytic
diﬀerentiation, cells were initially grown in standard DMEM
growth medium in 6-well plates at a density of 0.3× 106 cells/
ml. Once 90–100% conﬂuence was reached, the medium was
replaced with DMEM supplemented with adipogenic
induction mixture, containing 10% FBS, 10% horse serum
(Sigma), 1% pen/strep, 100 nM dexamethasone, 0.45mM iso-
butyl methylxanthine [41] (Sigma), 3μg/ml insulin (Sigma),
and 1μM rosiglitazone [42] (Novo Nordisk, Bagsvaerd,
Denmark). The medium was replaced 3 times per week,
and cells cultured in parallel in standard culture medium
were used as controls.
4.4. Cytochemical Staining
4.4.1. Alizarin Red S Staining for Mineralized Matrix. Once
cells had grown suﬃciently, the cell monolayer was washed
with phosphate-buﬀered saline (PBS) and then ﬁxed with
4% paraformaldehyde for 15 minutes at room temperature.
Cells were then rinsed 3 times in distilled water and stained
with 2% alizarin red S Stain (Cat. number 0223; ScienCell,
Carlsbad, CA, USA) for 20–30 minutes at room temperature.
Cells were washed further 3–5 times with water to remove
excess dye and then stored in water to prevent them drying
out. Cells were then visualized using an inverted microscope
(ZEISS AX10). To quantify alizarin red S staining, and hence
mineralization, plates were air dried, and then the alizarin red
S dye was eluted by adding 800μl acetic acid to each well and
incubating for 30 minutes at room temperature, as described
previously [43]. The stain was then quantiﬁed by measuring
the absorbance at 405 nm with an Epoch spectrophotometer
(BioTek Inc., Winooski, VT, USA).
4.4.2. OsteoImage Mineralization Assay. The formation of
mineralized matrix in vitro was quantiﬁed using an Osteo-
Image mineralization assay kit according to manufacturer’s
instructions (Cat. number PA-1503; Lonza, USA). Brieﬂy,
culture medium was removed, and cells were washed once
with PBS and then ﬁxed with 70% cold ethanol for 20
minutes. Next, diluted staining reagent was added at a level
recommended by the manufacturer, and plates were incu-
bated in the dark for 30 minutes at room temperature. The
cells were then washed, and staining was quantiﬁed using a
ﬂuorescence plate reader (Molecular Devices Co., Sunnyvale,
CA, USA) with excitation and emission wavelengths of 492
and 520nm, respectively.
Table 4: Genes involved in both osteogenesis- and adipogenesis-related pathways that are signiﬁcantly changed in TGFβ-treated cells and
CYD-treated cells.
Endochondral ossiﬁcation Actin cytoskeleton Focal adhesion TGFB signaling MAPK signaling Adipogenesis
TGFB2 FGF1 CAV2 NEDD9 TGFB2 EGR2
FGF2 FGF2 MAPK8 MAPK8 MAPK8 IRS1
PLAT KRAS LAMC2 KRAS MEF2D
DUSP1
TGFB
FGF2
Actin
cytoskeleton
FGF2
TGFB2
PLAT
EG
R2
ME
F2D
IRS
1
FGF2
1
TMS
B4X
GNA
13
PDGF
A
FGF1
A
ENAMSN
GSN
KRASCYD
Osteogenesis
CYD
Adipogenesis
MRA
5
SOS2
PDGF
3
Figure 7: TGFβ1 signaling in hMSC diﬀerentiation. Schematic showing how TGFβ and CYD aﬀect hMSC osteogenic and adipogenic
diﬀerentiation through the modulation of genes associated with the actin cytoskeletal pathway. Suggested downstream targets are also shown.
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4.4.3. Oil Red O Staining for Lipid Droplets. Cytoplasmic lipid
droplets within mature adipocytes were visualized using Oil
red O staining. Cells were washed with PBS, ﬁxed in 4%
formaldehyde for 10 minutes at room temperature, rinsed
once with 3% isopropanol, and then stained for 1 hour at
room temperature with ﬁltered Oil red O staining solution
(prepared by dissolving 0.5 g Oil red O powder in 60% iso-
propanol). In order to quantify mature adipocytes, Oil red
O stain was eluted from cells by adding 100% isopropanol
to each well, and then the absorbance at 510 nm was mea-
sured using an Epoch spectrophotometer.
4.4.4. Nile Red Staining for the Quantiﬁcation of Mature
Adipocytes. A 1mg/ml stock solution of Nile red ﬂuorescent
stain was prepared in DMSO and stored in the dark at −20°C.
Cultured undiﬀerentiated and diﬀerentiated cells were
ﬁxed in 4% paraformaldehyde (Sigma) for 15 minutes
and then washed once with PBS. PBS was then removed,
and cells were stained with 5μg/ml Nile red stain in PBS
for 10 minutes at room temperature. The ﬂuorescence sig-
nal was measured using a SpectraMax/M5 ﬂuorescence
spectrophotometer (Molecular Devices Co.) in bottom-
well scan mode. Nine readings were taken per well using
excitation and emission wavelengths of 485nm and
572nm, respectively.
4.5. Quantitative Real-Time PCR (qRT-PCR). Total RNA was
extracted from cells using a PureLink RNA mini kit (Cat
number 12183018A; Ambion, USA) according to manu-
facturer’s recommendations and quantiﬁed using a Nano-
Drop 2000 spectrophotometer (Thermo Scientiﬁc, USA).
Complementary DNA (cDNA) was synthesized from 1μg
RNA using a high-capacity cDNA reverse transcription
kit (Applied Biosystems, USA) and a MultiGene thermal
cycler (Labnet) according to manufacturer’s instructions.
Relative mRNA levels were inferred from the cDNAs
using Power SYBR Green master mix (Applied Biosystems,
UK) and TaqMan Universal master mix II, no UNG
(Applied Biosystems, USA), both according to manufac-
turer’s instructions, and a real-time PCR detection system
(Applied Biosystems). Relative mRNA levels were normal-
ized to the reference gene GAPDH, and then gene expres-
sion quantiﬁcation was performed using a comparative Ct
method, wherein ΔCT is deﬁned as the diﬀerence between
the target and reference gene CT values. Primers are listed
in Supplementary Tables S7 and S8. These primers were
either TaqMan primers (Applied Biosystems) or custom
primers whose sequences have been published previously.
4.6. Global Gene Expression Proﬁling by Microarray. Total
RNA was extracted from cells using a PureLink RNA mini
kit, according to manufacturer’s recommendations. One
hundred and ﬁfty nanograms of total RNA was then
labeled and hybridized to a SurePrint G3 Human GE
8× 60K microarray chip (Agilent Technologies). All micro-
array experiments were conducted by the Microarray Core
Facility (Stem Cell Unit, College of Medicine, King Saud Uni-
versity). Normalization and data analyses were performed
using GeneSpring GX software (Agilent Technologies), and
pathway analysis was conducted using the Single Experiment
Pathway analysis feature of the GeneSpring 12.0 software
package (Agilent Technologies) as described previously
(66). In addition, we used the web-based software DAVID
Bioinformatics Resources 6.8, where all genes that were
upregulated by TGfb were uploaded into DAVID and sig-
naling pathways were achieved. Signiﬁcant changes were
deﬁned as a fold change of ≥2 and p < 0 02.
4.7. Cell Proliferation Assays
4.7.1. AlamarBlue Cell Viability Assay. Cell viability was mea-
sured using alamarBlue assay reagent (AbD Serotec, Raleigh,
NC, USA) according to manufacturer’s recommendations.
Brieﬂy, cells were cultured in 96-well plates in 100μl of the
appropriate medium before 10μl alamarBlue substrate was
added at the indicated time points. Plates were then incu-
bated in the dark at 37°C for 1 hour. AlamarBlue ﬂuorescence
was then detected using a Synergy II microplate reader (Bio-
Tek Inc.) with excitation and emission wavelengths of
530 nm and 590nm, respectively.
4.8. RTCA Cell Proliferation Assay. An xCELLigence RTCA
(real-time cell analysis) DP system (ACEA Biosciences Inc.,
San Diego, CA) was used to measure the rate of cellular pro-
liferation according to manufacturer’s protocol. Brieﬂy,
100μl DMEM supplemented with 10% FBS was loaded onto
each well of an E-plate 16 chamber slide, which was then
placed inside the humidiﬁed incubator of the RTCA DP
analyzer for 1 hour at 37°C to allow the membrane surface
and medium to equilibrate. After 1 hour, background
measurements were performed. Next, 5000 cells/100μl
DMEM+10% FBS were added per well, and measure-
ments were recorded at 15-minute intervals for various
total durations, depending on the experimental setup.
4.9. Transmission ElectronMicroscopy (TEM). For TEM, cells
were trypsinized, washed with PBS, pelleted, and then ﬁxed
in 2.5% glutaraldehyde (Cat. number 16500; Electron
Microscopy Sciences) in 0.1M phosphate buﬀer (pH7.2) at
4°C for 4 hours. Next, the cells were washed in 0.1M phos-
phate buﬀer (pH7.2) 3 times for 30 minutes each and then
treated with 1% osmium tetroxide (OsO4) in 0.1M phos-
phate buﬀer (pH7.2) for 2 hours. Cells were then dehydrated
in increasing concentrations of ethanol (10%, 30%, 50%,
70%, 90%, and 100%) for 15 minutes each, before being
resuspended in acetone and incubated for 15 minutes. The
resulting cell suspension was then aliquoted into BEEM®
embedding capsules and inﬁltrated ﬁrstly with a 2 : 1 aceto-
ne : resin mixture for 1 hour and secondly with a 1 : 2 aceto-
ne : resin mixture for 1 hour. Following inﬁltration, the
BEEM capsules were centrifuged at 2500 rpm for 5 minutes
and embedded in pure resin for 2 hours. The resin was then
polymerized by baking in an oven at 70°C for 12 hours. Semi-
thin sections (0.5μm thickness) were prepared and stained
with 1% toluidine blue. Ultrathin sections (70 nm thick-
ness) were prepared and mounted on copper grids and
then stained ﬁrstly with uranyl acetate (saturated ethanol
solution) for 30 minutes, rinsed with double distilled water
and then stained with Reynold’s lead citrate solution for 5
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minutes before a ﬁnal rinse with distilled water. The con-
trasted ultrathin sections were examined and photographed
under a JEOL 1010 transmission electron microscope (JEOL,
Tokyo, Japan).
4.10. Statistical Analysis. All results are presented as the
mean± SD of at least 3 independent experiments. Diﬀerences
between groups were assessed using Student’s t-test, and
p values < 0.05 were considered statistically signiﬁcant.
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Supplementary Materials
Supplementary 1. Figure S1: DAVID microarray functional
gene analysis. One thousand nine hundred genes were
uploaded to DAVID online software. KEGG pathway analy-
sis showed many interested pathways which are upregulated
after TGFb-1 treatment of hBMCs. Here, we show the top
most upregulated pathways which include key osteoblast dif-
ferentiation pathways.
Supplementary 2. Table S1: whole genome microarray
mRNA data showing gene ENTITIES for TG1 versus CNT
DOWN 1298 genes.
Supplementary 3. Table S2: whole genome microarray
mRNA data showing gene ENTITIES for TG1 versus CNT
UP 1932 genes.
Supplementary 4. Table S3: upregulated biological processes
and related genes in TGFB1-treated cells using GO analysis.
Supplementary 5. Table S4: ultrastructural characteristics of
CL1 cells under diﬀerent treatment conditions.
Supplementary 6. Table S5: whole genome microarray
mRNA data showing gene entities for CYD versus CNT up
to 10,855 genes.
Supplementary 7. Table S6: whole genome microarray
mRNA data showing gene entities for CYD versus CNT
DOWN 2523 genes.
Supplementary 8. Table S7: real-time PCR human primer
sequences used in this study.
Supplementary 9. Table S8: TAQMAN real-time PCR primers.
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